Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

ABP 215 is a biosimilar product to bevacizumab. Bevacizumab acts by binding to vascular endothelial growth factor A, inhibiting endothelial cell proliferation and new blood vessel formation, thereby leading to tumor vasculature normalization. The ABP 215 analytical similarity assessment was designed...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Neungseon, Polozova, Alla, Zhang, Mingxuan, Yates, Zachary, Cao, Shawn, Li, Huimin, Kuhns, Scott, Maher, Gwendolyn, McBride, Helen J., Liu, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973752/
https://www.ncbi.nlm.nih.gov/pubmed/29553864
http://dx.doi.org/10.1080/19420862.2018.1452580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973752/
https://www.ncbi.nlm.nih.gov/pubmed/29553864
http://dx.doi.org/10.1080/19420862.2018.1452580

Ejemplares similares